| Name | Title | Contact Details |
|---|---|---|
Frank Jordan |
Director HR Data Reporting and Analytics | Profile |
Colleen Peterson |
Executive Director Human Resources | Profile |
Stephanie Lam |
Associate Director Human Resources, HRBP | Profile |
Bart Cornelissen |
Vice President Corporate Finance | Profile |
Karen Manalang |
Associate Director, Accounting | Profile |
Arnel Inc is a Parlin, NJ-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
Sequenom is a leading high-performance DNA analysis company organized into two distinct business units:Sequenom Genetic Systems and Sequenom Pharmaceuticals.
PolarityTE, is the owner of a novel regenerative medicine and tissue engineering platform developed and patented by Denver Lough MD, PhD. This radical and proprietary technology employs a patients` own cells for the healing of full-thickness functionally-polarized tissues. If clinically successful, the PolarityTE platform will be able to provide medical professionals with a truly new paradigm in wound healing and reconstructive surgery by utilizing a patient`s own tissue substrates for the regeneration of skin, bone, muscle, cartilage, fat, blood vessels and nerves. It is because PolarityTE uses a natural and biologically sound platform technology, which is readily adaptable to a wide spectrum of organ and tissue systems, that the company and its world-renowned clinical advisory board, are poised to drastically change the field and future of translational regenerative medicine.
Allena Pharmaceuticals is dedicated to developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic disorders that affect the kidney. The company is focused on metabolic disorders that result in excess accumulation of certain metabolites, such as oxalate and urate, that can cause kidney stones, damage the kidney, and potentially lead to chronic kidney disease, or CKD, and end-stage renal disease. Allena`s proprietary technological approach enables the design, formulation and delivery of non-absorbed and stable enzymes orally and in sufficient doses for activity in the GI tract. This approach utilizes the GI tract to degrade metabolites, such as oxalate and urate, reducing plasma and urine levels, and in turn, reducing their disease burden on the kidney over time.
We use our natural plant-based technologies to protect crops and harvested produce, helping to eliminate food spoilage and reduce reliance on chemicals. Accomplishing our mission means we will waste less food, water and energy, helping to preserve our natural ecosystems while creating economic opportunities for the 500 million small family farms worldwide. In the future, less food will be wasted, we will use smarter, more natural methods for growing and protecting crops, and there will be an abundance of fresh food for everyone.